LRMR Share Price Performance
US$4.87
-1.78 (-26.77%)
Price US$4.87
Share PriceUS$4.87
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
May 28
Larimar Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
LRMR Community Narratives
There are no narratives available yet.
Larimar Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.17
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Larimar Therapeutics, Inc. Competitors
Snowflake Analysis
About LRMR
- Founded
- n/a
- Employees
- 65
- CEO
- WebsiteView website
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.6%
- 3 Months: 7.6%
- 1 Year: 18.7%
- Year to Date: 14.7%
The market has climbed 1.6% in the last 7 days, lead by the Information Technology sector with a gain of 2.8%. The market is up 19% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›